Abstract | Eosinophils are multifunctional granular leukocytes that are implicated in the pathogenesis of a wide variety of disorders, including asthma, helminth infection, and rare hypereosinophilic syndromes. Although peripheral and tissue eosinophilia can be a feature of many types of small-vessel and medium-vessel vasculitis, the role of eosinophils has been best studied in eosinophilic granulomatosis with polyangiitis (EGPA), where eosinophils are a characteristic finding in all three clinical stages of the disorder. Whereas numerous studies have demonstrated an association between the presence of eosinophils and markers of eosinophil activation in the blood and tissues of patients with EGPA, the precise role of eosinophils in disease pathogenesis has been difficult to ascertain owing to the complexity of the disease process. In this regard, results of clinical trials using novel agents that specifically target eosinophils are providing the first direct evidence of a central role of eosinophils in EGPA. This Review focuses on the aspects of eosinophil biology most relevant to the pathogenesis of vasculitis and provides an update of current knowledge regarding the role of eosinophils in EGPA and other vasculitides.
Introduction
Historically, the role of eosinophils in vasculitis has been studied primarily in the setting of eosinophilic granulo matosis with polyangiitis (EGPA), where periph eral and tissue eosinophilia are, by definition, increased. Eosinophilia where eosinophils account for >10% of peripheral white blood cells and extra vascular eosinophilia are two of six criteria used to distinguish EGPA from other vasculitides, according to the 1990 ACR classification cri teria. 1 However, as noted in the 1994 Chapel Hill nomenclature of systemic vasculi tides, an abundance of eosinophils in inflammatory infiltrates is not specific to EGPA and has been reported in other types of small-vessel and medium-vessel vasculitis, most notably granulomatosis with polyangiitis (GPA). 2 Eosinophilia is not a feature of large-vessel vasculitis. Despite the presence of peripheral and tissue eosinophilia in patients with vasculitis, studies demonstrating a direct pathogenic role of eosinophils in vasculitis are lacking. The fact that there is no widely accepted animal model of eosinophilic vasculitis has been particularly limiting in this regard. Nevertheless, eosinophils have been studied extensively in other disorders and their impact on tissue damage 3 and localization to sites of vascular damage in some settings 4, 5 have been extrapolated as evidence for their role in the pathogenesis of eosinophilic vasculitis. The contribution of the eosinophil to the pathophysiology of EGPA is now being investi gated in clinical trials using therapies that specifically target eosinophils. This Review summarizes the basic biology of eosinophils, with a focus on the features of eosinophils implicated in disease pathogenesis. The role of eosinophils and eosinophil activation in EGPA and other vasculitides is also discussed.
Characteristics of eosinophils
Peripheral blood eosinophils are terminally differentiated myeloid cells that develop in the bone marrow under the influence of a number of transcription factors, including GATA-binding factor 1 (GATA-1, also known as erythroid transcription factor), and cytokines, including IL-3, IL-5 and granulocyte-macrophage colonystimulating factor (GM-CSF) ( Figure 1 ). Although IL-5 is the key cytokine mediating the release of eosinophils into the bloodstream and recent data suggests that local secretion of IL-5 by type 2 innate lymphoid cells in the tissues might have an important role in tissue accumulation of eosinophils, 6 various chemo kines and other soluble mediators have been implicated in directing circulating eosinophils to bind with selectins and integrins and thereby traffic into tissues. These mediators include the eotaxin chemokines (CC-chemokine ligand [CCL] 11, also known as eotaxin; CCL24, also known as eotaxin 2; and CCL26, also known as eotaxin 3), which are expressed in multiple tissues, CCL5 (also known as RANTES) produced by T cells as well as eosinophils, CCL28 produced on epithelial surfaces, 7 and other nonchemokine factors such as complement factor C5a and platelet activating factor.
In healthy individuals, the vast majority of eosinophils (>90%) reside in the tissues, where they can be found in the gastrointestinal tract, spleen, lymph nodes, thymus, mammary glands and uterus. In disease states, how ever, eosinophils can move along chemokine gradients produced on epithelial surfaces or vascular endothelium to sites of inflammation in many different tissues (Figure 2 ).
Eosinophil structure
First described by Ehrlich in 1879, the eosinophil was so named because of the exuberant staining of its secondary granules with the red dye eosin. These eosinophilspecific granules contain cationic proteins including major basic protein (MBP), eosinophilic cationic protein (ECP), eosinophil peroxidase (EPO), and eosinophil derived neurotoxin (EDN), as well as a wide variety of preformed cytokines, growth factors and enzymes, all of which can be selectively released upon cell activation (reviewed in detail elsewhere [8] [9] [10] ). These preformed mediators include T H 2-type cytokines (IL-4, IL-5, IL-13) and chemokines (CCL11 [eotaxin], CCL3, CCL5). Eosinophils are also characterized by primary granules, which contain Charcot-Leyden crystal proteins, 11 and lipid bodies, which are com plex inducible organelles that are the site of eicosanoid s ynthesis and release during eosinophil activation. 12 
Degranulation
The eosinophil has long been thought of as a toxic effector cell that releases its granules' contents either by mechanical disruption (cytolysis) or via activating signals. This reductive viewpoint has been challenged in the past decade as more has been discovered about the mechanisms of eosinophil granule release. Eosinophils can degranulate by exocytosis, whereby cell contents are released by fusion of intracellular granules or sombrero vesicles 13 with the plasma membrane. Piecemeal degranu lation, by contrast, results in differential secretion of individual granule contents from activated eosinophils without disruption of the cell membrane, [13] [14] [15] and is the probable mechanism by which eosinophils modulate inflammatory action in response to selective stimuli. 16 Some studies have demonstrated that granules released via cytolysis can remain viable outside of the cell. These 'cell-free granules' have been shown to function as secretory organelles and can be differentially stimulated by ligands of cysteinyl leukotriene receptors 17 or by ligands of cytokine receptors. 18 The complex regulation of eosinophil degranulation and release of mediators in vessel walls and perivascular Immunostaining with antibodies against eosinophil granule proteins has been used to demonstrate extracellular granule protein deposition in a variety of tissue specimens, including biopsy-obtained skin samples from patients with EGPA. 20 The relative contributions of piecemeal degranulation and cytolysis to this process have been more difficult to ascertain, although a 2014 electron microscopic study of esophageal biopsy specimens from patients with eosinophilic esophagitis suggests that cytolytic release of cell-free granules could be more important than previously recognized. 21 The eosinophil: a jack of all trades In keeping with the large number and variety of surface receptors, cytokines and other mediators produced by eosinophils, it is becoming increasingly clear that the traditional paradigm of the eosinophil as a toxic effector cell is incomplete. 22, 23 Although eosinophils are probably important in host defense against helminths, tumour surveillance and allergic inflammation, accumulating data supports a role for eosinophils in more homeostatic functions, including tissue repair and remodelling 24 and maintenance of plasma cells in the bone marrow 25 and of alternatively activated macrophages in adipose tissue. 26 
Eosinophil-associated tissue damage
The eosinophil orchestrates organ-specific and diseasespecific tissue damage through direct cytotoxic effects (for example, deposition of eosinophil granule proteins or release of reactive oxygen species) or indirectly as a result of recruitment and activation of other inflammatory cells. Although the resulting clinical manifestations depend, to a large degree, on the particular tissue involved, complications of eosinophil accumulation and activation include tissue fibrosis, thrombosis, and allergic inflammation.
Eosinophil-mediated fibrogenesis
Eosinophilic infiltrates and deposition of eosinophil granule proteins have been demonstrated in fibrotic tissues from many different organs 27 and in a variety of clinical disorders, including asthma, 28-31 eosinophilic esophagitis, 21, 32 and hypereosinophilic syndromes. Although these observations provide circumstantial evidence that eosinophils play a part in tissue fibro genesis, more-direct support for this hypothesis comes from in vitro studies, in which eosinophils and eosinophil products have been shown to promote collagen synth esis and fibroblast proliferation, 33 and from in vivo studies in eosinophil-deficient mice (ΔdblGATA mice), demonstrating decreased airway extracellular matrix deposition following allergen challenge in the absence of eosinophils. 34 Eosinophils seem to contribute to tissue fibrosis through multiple mechanisms, including ECP-mediated stimulation of collagen contraction 35 and release of fibrogenic cytokines (such as transforming growth factor β and IL-1β).
36,37
Eosinophils and thrombosis The risk of thromboembolism is increased in a range of disorders associated with marked peripheral eosinophilia, including eosinophilic myeloproliferative disorders, idiopathic hypereosinophilic syndrome, and eosinophilic vasculitis. 38 Although the mechanism of eosinophil-induced hypercoagulability is not entirely clear, contributing factors probably include initiation of the clotting cascade by tissue factor (released during eosinophil degranulation), 39 inhibition of vascular endothelial thrombomodulin (a potent anticoagulant) by MBP, 40, 41 and activation of platelets by MBP and EPO. 42 Eosinophils and allergic inflammation Peripheral eosinophilia is common in patients with aller gic disorders, such as allergic rhinitis, eosinophilic esophagitis, and atopic dermatitis. Furthermore, eosinophils and eosinophil granule proteins can be demonstrated in body fluids and biopsy specimens from patients with allergic disorders including asthma. Eosinophilic inflammation and its role in asthma pathogenesis have been shown in animal models of allergic asthma, with granule proteins being shown to worsen bronchoprovocation 28 and hyperresponsiveness. 29 In humans, ECP levels in bronchoalveolar lavage fluid 
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Figure 1 | Characteristics of eosinophils. Eosinophils are multifunctional, bi-lobed granulocytes that contain granular proteins including MBP, ECP, EPO and EDN. Eosinophils can degranulate by exocytosis or by piecemeal degranulation whereby individual granule contents are differentially secreted by activated eosinophils without disruption of the cell membrane. Sombrero vesicles are morphologically distinct vesicles that carry granules to the plasma membrane. Lipid bodies are structurally distinct sites within eosinophils that are responsible for synthesis of paracrine eicosanoid mediators of inflammation. Functions of eosinophils include the production of numerous chemokines, cytokines, and growth factors that mediate allergic inflammation, thrombosis, and fibrosis. A nonexhaustive list of these products are shown in boxes. Abbreviations: 15-HETE, 15-hydroxyeicosatetraenoic acid; APRIL, a proliferation-inducing ligand; CCL, CC-chemokine ligand; CCR, CC-chemokine receptor; CXCL, CXC-chemokine ligand; CXCR, CXC-chemokine receptor; ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; EPO, eosinophil peroxidase; GM-CSF, granulocytemacrophage colony-stimulating factor; GRO-α, growth regulated-α protein; LIF, leukaemia inhibitory factor; LT, leukotriene; MBP, major basic protein; NGF, nerve growth factor; PAF, platelet activating factor; PDGF, platelet-derived growth factor; SCF, stem cell factor; TF, tissue factor; TGF, transforming growth factor; VEGF, vascular endothelial growth factor.
correlate with asthma severity, 30 and MBP is seen in mucus plugs and on epithelial surfaces of lung sections of fatal acute severe asthma (formerly referred to as status asthmaticus). 31 Further validation of eosinophil granule proteins as clinical disease biomarkers in asthma and EGPA is ongoing.
Eosinophils and nerves
Eosinophils can affect nerves and nerve function in a variety of ways. Axonal neuropathy as well as neurogenic atrophy of related muscle have been shown in nerve and muscle biopsy specimens from patients with hyper eosinophilic syndromes, 43, 44 and a sural nerve biopsy performed in a patient with eosinophilic vasculitis showed perivascular infiltration with eosinophilia. 45 Eosinophils can localize to cholinergic nerves in the setting of asthma, where they release MBP upon contact. 46 They have also been shown to induce neuronal retraction in vitro via a contact-dependent mechanism. 47 Taken together, these findings suggest that eosinophils can directly injure nerve tissue, although nerve ischaemia due to eosinophilic infiltration of blood vessel walls might be the predominant mechanism of nerve damage in the mononeuritis multiplex seen in EGPA.
EGPA
The role of eosinophils in vasculitis is best characterized in EGPA. In 1951, Churg and Strauss first reported a form of systemic vasculitis defined, in part, by profound blood and tissue eosinophilia (Figure 3) . 48 Adult-onset asthma, granulomatous inflammation and small-vessel vasculitis were also salient features in patients with this dis order. In 2012, the eponymic name of this condition was changed from Churg-Strauss Syndrome to eosinophilic granulomatosis with polyangiitis (EGPA) to promote nomenclature reflective of disease pathology. 49 Although the eosinophil is considered to have a prominent role in the clinical manifestations of EGPA, the precise mechanisms of eosinophil-mediated in flammation remain to be fully elucidated.
EGPA is characterized by three overlapping phases of disease that progress at variable intervals: asthma and other allergy symptoms; tissue and blood eosinophilia; and necrotizing vasculitis. 50 EGPA preferentially affects certain organ systems, including the airways, peripheral nerves, heart, kidney, and gastrointestinal tract. 51, 52 Antineutrophil cytoplasmic antibodies (ANCAs) have been demonstrated in approximately 30-40% of patients with EGPA. 53, 54 Whether the presence or absence of ANCA defines distinct subgroups of disease pathogenesis is unclear, although constitutional symptoms, peripheral neuropathy, and glomerulonephritis are more common in patients with ANCA-positive EGPA, whereas cardiac involvement is more frequent in patients who are ANCA-negative. 55, 56 Despite the fact that relapses of vasculitis seem to be more frequent in ANCA-positive EGPA, mortality might be higher in ANCA-negative EGPA, presumably related to increased cardiac involvement. 51 Definitive diagnosis of EGPA relies on demonstration of vasculitis in tissue. It is unclear whether ANCApositivity is an appropriate diagnostic surrogate for vasculitis. In the absence of proven vasculitis, the clinical and laboratory features of EGPA share considerable overlap with other hypereosinophilic syndromes, making it potentially difficult to distinguish between the conditions. 57, 58 There are no known causal triggers of EGPA. 59 Disease onset typically occurs in people aged 40-60 years, and there is no known sex, familial, or ethnic predisposition. Candidate-gene association studies, including positive and negative disease associ ations with various HLA class II polymorphisms, 60 implicate potential immunogenetic factors.
Eosinophils in EGPA pathology
To what extent eosinophils have a primary role in the pathogenesis of EGPA, rather than a secondary role as mediators of organ damage, is unknown. Eosinophils are involved in all three stages of the pathology of EGPA.
As described above, eosinophils are implicated in the first stage of EGPA, in which asthma is the defining feature and which parallels an asthma phenotype known as nonallergic eosinophilic asthma. 61 This type of asthma often develops in adulthood, is associated with chronic rhinosinusitis and/or nasal polyposis, and frequently requires treatment with high doses of systemic corticosteroids for adequate symptom control. 62 Increased numbers of eosinophils in the sputum and elevated levels of sputum eosinophil granule proteins are typical. 63 By definition, eosinophils are present in the second stage of EGPA-blood and tissue eosinophilia. The characteristic histopathologic findings of the third stage of EGPA, which include eosinophilic infiltration in tissue, eosinophilic vasculitis of the small arteries and veins, and eosinophilic granulomas, 64 reflect the central role of eosinophils in this type of vasculitis. Granulomas in EGPA tend to have a centralized zone of eosinophilic necrosis surrounded by palisading histiocytes and multi nucleated giant cells (Figure 2) . 65 The different histopatho logic findings of EGPA can be affected by treatment and are rarely found simultaneously in a single patient. 66 Organ-specific pathology in EGPA can be the result of direct eosinophilic infiltration of the tissue and/or ischaemic damage attributable to the occlusion of small arteries by inflammatory-cell infiltration or clotting. For example, cardiac manifestations of EGPA include eosino philic myocarditis, endomyocardial fibro sis, eosinophilic pericarditis, and myocardial infarction due to eosinophilic coronary arteritis.
Immunopathogenesis of EGPA
Although a direct role of ANCAs in disease pathogenesis is generally accepted in other types of ANCA-associated vasculitis (AAV), there is currently no evidence for a direct pathogenic role of ANCAs in EPGA. Rodent models of both myeloperoxidase (MPO)-AAV and proteinase 3 (PR3)-AAV have been developed but do not feature prominent eosinophilic involvement. 67, 68 An IgE-mediated cutaneous reverse passive Arthus reaction model has been used to induce eosinophil-rich cutaneous vasculitis in wild-type C57Bl/6 mice and to demonstrate a key role for P-selectin and CCL7 (monocyte chemotactic protein 3) in recruitment of eosinophils to cutaneous lesions; 69 however, this model is not suitable for studies of systemic immunopathogenesis since the reaction is limited to the skin.
Given the lack of a suitable animal model for EGPA, disease pathogenesis is inferred largely from clinical studies. EGPA has traditionally been considered a T H 2-mediated disease, from its striking early presentation with allergic inflammation to the elevation of T H 2-type cytokine levels in the circulation that are thought to contribute to the recruitment, activation, and delayed apoptosis of eosinophils. 70, 71 There is evidence of oligoclonal expansion in EGPA, and activated CD4 + type 2 T helper (T H 2) cells are prominent. 72 Furthermore, CCL17 (also known as thymus and activation-regulated chemokine), a chemokine that recruits T H 2 cells, is associated with active EGPA versus inactive disease and healthy controls. 57 Cytokines and chemokines that are produced by eosino phils, as well as those produced by other cell types, have been implicated in the pathogenesis of EGPA (Table 1) . For example, IL-25 is a cytokine produced by multiple different cell types that can enhance T H 2-type cytokine production. Eosinophils are a key source of IL-25 in EGPA, and serum concentration of IL-25 is associated with disease activity and correlates with eosinophil levels in EGPA, 73 supporting the concept that the pathogenesis of EGPA probably involves contributions from interactions between the innate and adaptive immune systems. Type 2 innate lymphoid cells, which can produce large amounts of T H 2-type cyto kines, including IL-5 and IL-13, have been identified in subsets of patients with nonallergic eosinophilic asthma, but have not been studied in EGPA. 74 Other T-helper responses are also likely to contribute to disease pathogenesis. CD4 + T-cell lines from patients with EGPA secrete high amounts of interferon-γ, a potent T H 1-type cytokine involved in vasculitis and granu loma formation, 70 and type 17 T helper (T H 17) cells are upregulated in peripheral blood lymphocytes in active EGPA. 75 Conversely, a decreased percentage of CD4 + CD25 high FOXP3 + regulatory T cells has been demonstrated in patients with active EGPA, compared with patients with asthma or chronic eosinophilic pneumonia, 76 and decreases in regulatory T-cell numbers can further differentiate frequently-relapsing from seldom-relapsing EGPA. 77 B-lymphocytes and humoral responses might also have a role in EGPA pathogenesis. Patients with active EGPA often have elevated serum levels of total IgE and IgE-containing immune complexes, 78 and B-cell depletion can induce disease remission, reduce serum levels of IL-5, and lower eosinophil counts in EGPA. 79 The clini cal utility of ANCA as a longitudinal biomarker in EGPA has not been defined. However, in other forms of AAV, ANCA titres do not reliably correlate with disease activity or predict relapse. 80 Increased serum IgG4 levels and IgG4:IgG ratios have been demonstrated in patients with active EGPA in comparison with healthy individuals, patients with GPA, and patients with asthma. 
Eosinophil-related biomarkers in EGPA
Whereas the number of circulating eosinophils correlates with disease activity in untreated EGPA, absolute eosinophil counts might not be an adequate biomarker for individual patients because the association between eosinophil counts and disease activity is altered unpredictably by treatment with glucocorticoids and other immunosuppressive therapies. 82 Since glucocorticoid therapy is commonly needed to control symptoms of asthma and upper airway disease independent of systemic disease activity, 83 there has been particular interest in identifying reliable biomarkers of disease activity in EGPA that are unaffected by glucocorticoids.
Sputum eosinophil counts have been proposed as a biomarker in EGPA, but the evidence is limited. In one small study, eosinophil counts and ECP levels from induced sputum were significantly higher in three patients with active EGPA in comparison with 10 patients with stable glucocorticoid-dependent asthma. 84 In asthma, sputum eosinophil counts and ECP levels are typically increased but correlate only weakly with clinical markers of asthma severity. 85 Circulating levels of ECP have been associated with disease activity and peripheral eosinophil counts in EGPA. 86 Serum levels of a number of cytokines, chemokines, and surface receptors involved in eosinophil activation and recruitment have been proposed as potential biomar kers of disease activity in EGPA. The best studied of these is CCL26 (eotaxin 3), an eotactic chemokine produced by epithelial and endothelial cells. In one study, serum levels of CCL26, but not CCL11 (eotaxin) or CCL24 (eotaxin 2), correlated with eosinophil counts, total IgE levels, and acute inflammatory markers in 40 patients with EGPA and was not elevated in the serum of individuals with other eosinophilic or vasculitic disorders. 87 The utility of serum CCL26 levels for the diagnosis of active EGPA (sensitivity of 87.5% and specificity of 98.6%) was confirmed in a second study by the same authors. 88 Although serum levels of CCL17 89 and soluble IL-2 receptor 90 have been reported to be increased in the setting of active EGPA, they are also elevated in other eosinophilic disorders. 57 Eicosanoids, a family of hormones that includes prosta glandins, thromboxanes, and leukotrienes, might have proinflammatory effects in EGPA and other airway diseases. Case-control studies have linked EGPA onset to exposure to leukotriene receptor antagonists (LTRAs); however, these studies are subject to potential selection bias on the basis of asthma severity, a possible steroid-sparing effect upon initiation of medications used to treat asthma (including LRTAs) that could 'unmask' latent EGPA. 91 Urinary leukotriene E 4 correlates with disease activity in both EGPA and asthma, 92 and an arach id onic acid metabolite, 12-hydroxyleicosatetraenoic acid (12-HETE), could be a diseasespecific biomarker in EGPA. In one study, exhaled breath condensate from patients with EGPA was characterized by markedly elevated levels of 12-HETE in compari son with patients with asthma, hypereosinophilic syn dromes or healthy individuals, and levels of 12-HETE were also elevated in bronchoalveolar lavage fluid from patients with EGPA compared with patients with asthma; 12-HETE levels were not affected by concomitant use or dose of glucocorticoids. 93 
Therapeutics in EGPA
To date, no randomized controlled interventional trials have been performed in EGPA; therefore, treatment recommendations are based upon small pilot studies, expert opinion, and/or extrapolation from efficacious thera pies in other forms of vasculitis. [94] [95] [96] [97] In theory, therapies that modulate the production, recruitment, or survival of eosinophils might have efficacy in EGPA. Glucocorticoids reduce the number of eosinophils in the blood and tissues through mechanisms that promote cell death and clearance, and are a mainstay of therapy for EGPA. 98 The five-factor score (FFS), which is used to evaluate prognosis at diagnosis, can be used to guide therapeutic decisions in EGPA. 99 In patients with a poor prognosis, defined as a FFS ≥1, intensive therapy with both glucocorticoids and cyclophosphamide has been shown to improve survival. 99 Medications such as azathioprine and methotrexate are also used as steroid-sparing agents in milder disease or for maintenance of remission. IFN-α therapy can inhibit eosinophil recruitment 100 and has been used to induce remission in EGPA. However, given the numerous adverse effects and lack of convincing efficacy data, therapeutic use of IFN-α has been restricted to patients unable to tolerate conventional immuno suppressive therapies. 101 Efficacy of rituximab as induction therapy in both ANCA-positive and ANCAnegative cases of EGPA has been reported in small case series, 79, 102 highlighting the potential importance of humoral immun ity in EGPA. Adjunctive therapy with intravenous immunoglobulin might also be beneficial. 103 As previously mentioned, IL-5 is an eosinophilspecific cytokine that has key roles in the proliferation and maturation of eosinophil progenitors and in the migration and survival of mature eosinophils. Many of the commercially available agents used to treat EGPA can reduce IL-5 levels, including glucocorticoids, 104 rituximab, 79 and IFN-α, 100 and promising early results are emerging from studies using a humanized anti-IL-5 antibody, mepolizumab, as remission maintenance therapy in EGPA. [105] [106] [107] A large multicentre trial of mepolizumab is currently underway.
108

Eosinophils in other vasculitides
Peripheral and tissue eosinophilia has been reported in AAV other than EGPA, typically at mild to moderate levels. [109] [110] [111] [112] [113] [114] [115] In fact, some patients with GPA fulfill the 1990 ACR criteria for EGPA on the basis of eosinophilia and overlapping clinical symptoms. 114 Eosinophilia has also been reported in Kawasaki disease, with mild peripheral eosinophilia noted in 22-36% of patients at the time of diagnosis and prominent eosinophilic infiltrate demonstrated in the epicardial microvasculature of patients who died from Kawasaki disease. [116] [117] [118] Drug-induced vasculitis can also feature prominent REVIEWS eosinophilia, 4 and a high degree of tissue eosinophilia in biopsy-obtained samples of purpuric lesions has been proposed as a means to differentiate this condition from other forms of cutaneous small-vessel vasculitis. 119 Despite the association between eosinophilia and vasculitides other than EGPA, the role of eosinophils in disease pathogenesis in these conditions remains unclear since eosinophilia is not universally present and few studies have been performed in patients with eosinophilia and vasculitides other than EGPA. Further complicating the issue, some of the few studies that have explored eosinophilia in GPA have relied on assays of ECP or EDN in tissue or body fluids to document eosinophil activation. 110, 115 Whereas these assays might be useful in the setting of EGPA, where there is an overwhelming predominance of eosinophils, ECP and EDN are also present in neutrophils, 120 which are known to be pathogenic in AAV. 121 
Conclusions
Although the complexity of eosinophil biology is emerging within the context of eosinophilic diseases, including EGPA, significant gaps in our understanding of the role of eosinophils in vasculitis remain. Accumulating data from clinical studies of eosinophil-associated biomarkers and novel therapeutics that specifically target eosinophils are likely to provide new insights in this regard.
Review criteria
Two reviewers independently searched MEDLINE, EMBase (from 1980) and the Cochrane Library for full-text, Englishlanguage reviews and primary literature published up to February 2014, using the following MeSH terms: "eosinophils", "eosinophilia", "vasculitis", "antibodies", "antineutrophil cytoplasmic", "Churg-Strauss syndrome", and "Wegener's granulomatosis". Additional searches combined these MeSH terms with general terms such as "pathogenesis", "clotting", "thrombosis", "vascular", "neurologic", "granule protein", "damage", "organ involvement", "biomarker", "cytokine", "chemokine", "treatment", "diagnosis" and "clinical trials". Searches were also performed using the term "eosinophilic granulomatosis and polyangiitis". The reference lists of the articles selected were also searched for additional relevant articles or research studies.
